Doctors test One-Shot gene injection to fight rare blindness
NCT ID NCT05616793
Summary
This study is testing a new gene therapy called OPGx-001 for people with LCA5, a rare genetic condition that damages the retina and leads to vision loss. A small number of participants will receive an injection of the therapy into one eye to see if it is safe and if it might help preserve or improve vision. The study will also follow a group of untreated patients for 6 months to better understand how the disease naturally progresses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LCA5 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Retina Foundation of the Southwest
RECRUITINGDallas, Texas, 75231, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania Perelman School of Medicine
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.